Kiromic BioPharma Initiates Clinical Trial of Novel Treatment for Non-Small Cell Lung Cancer with Deltacel

Kiromic BioPharma, Inc. (NASDAQ: KRBP) is pleased to announce the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial of its proprietary cell therapy, KB-GDT-01 (also known as Deltacel).

This trial is designed to evaluate the potential of this innovative immuno-oncology therapy when combined with an anti-tumor therapy in the treatment of non-small cell lung cancer (NSCLC).

Leveraging its DIAMOND® artificial intelligence and data mining platform, Kiromic is committed to advancing the development of life-saving treatments for cancer patients.Deltacel is a revolutionary off-the-shelf Gamma Delta T-cell (GDT) therapy that is allogeneic, non-viral, and non-engineered.

By harnessing the power of cell therapy to tackle solid malignancies, such as Non-Small Cell Lung Cancer (NSCLC), Deltacel is seeking to fill a major gap in the global healthcare landscape and provide a much-needed solution to the millions of people afflicted by this debilitating disease.

Kiromic BioPharma is thrilled to announce a major milestone, achieved on March 31, 2023: the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).

This brings the company one step closer to beginning human clinical testing of a promising treatment option for the tens of thousands of patients living with non-small cell lung cancer, the leading cause of cancer deaths in the United States.

With this incredible science, Kiromic BioPharma is hopeful that it can provide a real solution to those suffering from this devastating disease.

About Kiromic BioPharma

Kiromic BioPharma, Inc., a clinical-stage biotherapeutics company, is revolutionizing the way cancer treatments are developed. With their proprietary DIAMOND® AI 2.0 target discovery engine, Kiromic is leveraging the power of data science and target identification to drastically reduce the time and cost associated with drug development.

Their multi-indication allogeneic cell therapy platform, which utilizes the natural potency of Gamma Delta T-cells to target solid tumors, is paving the way for a new era of cancer treatment. Headquartered in Houston, Texas, Kiromic BioPharma is unlocking the potential of AI-driven treatments to save lives.

Leave a Comment